Journal of clinical practice,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 20, 2024
Lung-on-a-Chip
(LoC)
is
a
microfluidic
device
that
simulates
the
gas-liquid
interface
of
human
pulmonary
alveoli
and
intended
for
pathophysiological,
pharmacological
molecular
biological
studies
blood-air
barrier
in
vitro.
The
LoC
includes
system
liquid
gas
microchannels
separated
by
semipermeable
elastic
membrane
containing
polymer
base
cellular
elements
alveoli.
Depending
on
type
(single-channel,
two-channel
three-channel),
may
contain
only
alveolocytes,
or
alveolocytes
combination
with
other
cells:
endothelial
cells,
fibroblasts,
alveolar
macrophages,
tumor
etc.
Some
models
also
include
hydrogel
stroma
interstitium.
first
LoC,
which
there
monolayer
cells
one
side
other,
was
developed
2010
group
Ingber
et
al.
at
Wyss
Institute
Harvard
University
order
to
reproduce
microenvironment
biomechanics
Modern
modifications
same
differ
design
system,
biomaterial,
composition
stromal
special
tasks
being
solved.
In
addition
barrier,
are
studying
specific
pathophysiological
processes,
screening
drugs,
modeling
particular
diseases,
such
as
lung
cancer,
COPD
asthma.
this
review,
we
analyzed
existing
varieties
biomaterials
used,
methods
detecting
processes
devices
main
areas
research
using
"Lung-on-a-chip"
technology.
Micromachines,
Journal Year:
2025,
Volume and Issue:
16(2), P. 201 - 201
Published: Feb. 10, 2025
Microfluidic
technology
plays
a
crucial
role
in
organ-on-a-chip
(OoC)
systems
by
replicating
human
physiological
processes
and
disease
states,
significantly
advancing
biomedical
research
drug
discovery.
This
article
reviews
the
design
fabrication
of
microfluidic
devices.
It
also
explores
how
these
technologies
are
integrated
into
OoC
platforms
to
simulate
environments,
highlighting
key
principles,
technological
advances,
diverse
applications.
Through
case
studies
involving
simulation
multiple
organs
such
as
heart,
liver,
lungs,
evaluates
impact
systems'
on
screening,
toxicity
assessment,
personalized
medicine.
In
addition,
this
considers
technical
challenges,
ethical
issues,
future
directions,
looks
ahead
further
optimizing
functionality
biomimetic
precision
OoCs
through
innovation,
emphasizing
its
critical
promoting
medicine
treatment
strategies.
Biofabrication,
Journal Year:
2024,
Volume and Issue:
16(4), P. 042006 - 042006
Published: Aug. 27, 2024
Abstract
Recent
years
have
seen
the
creation
and
popularization
of
various
complex
in
vitro
models
(CIVMs),
such
as
organoids
organs-on-chip,
a
technology
with
potential
to
reduce
animal
usage
pharma
while
also
enhancing
our
ability
create
safe
efficacious
drugs
for
patients.
Public
awareness
CIVMs
has
increased,
part,
due
recent
passage
FDA
Modernization
Act
2.0.
This
visibility
is
expected
spur
deeper
investment
adoption
models.
Thus,
end-users
model
developers
alike
require
framework
both
understand
readiness
current
enter
drug
development
process,
assess
upcoming
same.
review
presents
selection
based
on
comparative
-omics
data
(which
we
term
model-omics),
metrics
qualification
specific
test
assays
that
may
support
context-of-use
(COU)
assays.
We
surveyed
existing
healthy
tissue
ten
development-critical
organs
body,
provide
evaluations
suggestions
improving
model-omics
COU
each.
In
whole,
this
comes
from
perspective,
seeks
an
evaluation
where
are
poised
maximum
impact
roadmap
realizing
potential.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: July 22, 2024
Boswellia
carterii
(BC)
resins
plants
have
a
long
historical
background
as
treatment
for
inflammation,
indicated
by
information
originating
from
multiple
countries.
Twenty-seven
diterpenoids
been
identified
in
ethyl
acetate
and
total
methanol
BC,
comprising
seventeen
boscartins
of
the
cembrane-type
ten
boscartols
prenylaromadendrane-type
diterpenoids.
Moreover,
twenty-one
known
triterpenoids
also
found,
encompassing
nine
tirucallane-type,
six
ursane-type,
four
oleanane-type,
two
lupane-type.
The
hold
significant
position
pharmaceutical
chemistry
related
industries
due
to
their
captivating
biological
characteristics
promising
pharmacological
potentials.
Extraction
creation
assessment
nano
sponges
loaded
with
either
B.
plant
extract
or
DEX,
are
subjects
our
current
investigation.
With
use
ultrasound-assisted
synthesis,
were
produced.
entrapment
efficiency
(EE%)
medications
was
examined
using
spectrophotometry.
Nano
characterized
number
methods.
Within
sponges,
EE%
medicines
varied
between
98.52
±
0.07
99.64
1.40%.
sponges'
particle
sizes
105.9
15.9
166.8
26.3
nm.
Drugs
released
Korsmeyer-Peppas
concept.
In
respiratory
distressed
rats,
effects
BC
extract,
DEX
salt
formulations
(D1,
D5,
P1
P1),
tested.
Treatment
significantly
reduced
ICAM-1,
LTB4,
ILβ
4
levels
improved
histopathologic
profiles,
when
compared
positive
control
group.
its
sponge
formulation
showed
therapeutic
effects.
effect
may
be
synergism
both
formulation.
This
achieved
blocking
ICAM-1
LTB4
pathways,
therefore
counteracting
talc
powder.
European Journal of Pharmaceutical Sciences,
Journal Year:
2023,
Volume and Issue:
191, P. 106596 - 106596
Published: Sept. 26, 2023
Chronic
respiratory
diseases
and
infections
are
among
the
largest
contributors
to
death
globally,
many
of
which
still
have
no
cure,
including
chronic
obstructive
pulmonary
disorder,
idiopathic
fibrosis,
syncytial
virus
others.
Pulmonary
therapeutics
afford
untapped
potential
for
treating
lung
infection
disease
through
direct
delivery
site
action.
However,
ability
innovate
new
therapeutic
paradigms
will
rely
on
modeling
human
microenvironment
key
cellular
interactions
that
drive
disease.
One
feature
is
air-liquid
interface
(ALI).
ALI
techniques,
using
cell-culture
inserts,
organoids,
microfluidics,
precision
slices
(PCLS),
rapidly
developing;
however,
one
major
component
these
models
lacking—innate
immune
cell
populations.
Macrophages,
neutrophils,
dendritic
cells,
others,
represent
populations,
acting
as
first
responders
during
or
injury.
Innate
cells
respond
modulate
stromal
bridge
gap
between
innate
adaptive
system,
controlling
bodies
response
foreign
pathogens
debris.
In
this
article,
we
review
current
state
culture
systems
with
a
focus
suggest
ways
build
add
complexity
relevant
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 7, 2025
The
development
of
a
inhaled
nanodrug
delivery
assessment
platform
is
crucial
for
advancing
treatments
chronic
lung
diseases.
Traditional
in
vitro
models
and
commercial
aerosol
systems
fail
to
accurately
simulate
the
complex
human
respiratory
patterns
mucosal
barriers.
To
address
this,
we
have
developed
breathing
mucociliary-on-a-chip
(BMC)
platform,
which
replicates
mucociliary
clearance
dynamics
vitro.
This
allows
precise
analysis
drug
deposition
penetration,
providing
critical
insights
into
how
liposomes
other
nanocarriers
interact
with
tissues
under
various
airflow
conditions.
Our
results
reveal
that
penetrate
deeper
cellular
layer
high
shear
stress,
both
static
dynamic
airflows
distinctly
affecting
their
release
rates.
BMC
integrates
inhalation
functionality,
enabling
comprehensive
evaluation
efficacy.
approach
highlights
importance
optimizing
inhalable
systems,
improving
nanocarrier
design,
tailoring
dosages
strategies.
represents
significant
advancement
field
delivery,
offering
more
accurate
reliable
method
assessing
performance
therapies.
By
detailed
understanding
interactions
tissues,
this
supports
personalized
therapies
offers
promising
strategies
treating
pulmonary
diseases
development.
Frontiers in Allergy,
Journal Year:
2025,
Volume and Issue:
6
Published: March 28, 2025
Asthma
is
a
heterogenous
inflammatory
bronchial
disease
involving
complex
mechanisms,
several
pathways,
and
multiples
cell-type
networks.
Bronchial
inflammation
associated
to
asthma
consecutive
multiple
aggressions
on
epithelium,
such
as
microbiologic,
pollutant,
antigenic
agents,
which
are
responsible
for
both
T2
non-T2
responses
further
airway
remodeling.
Because
physiopathology
involves
crosstalk
between
cell
types
from
different
origins
(epithelial,
mesenchymal,
immune
cells)
numerous
cellular
effectors,
no
single
and/or
representative
in
vitro
model
suitable
study
the
overall
of
this
disease.
In
short
review,
we
present
discuss
advantages
limitations
models
decipher
aspects
virus-related
exacerbation.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(21), P. 11751 - 11751
Published: Nov. 1, 2024
Idiopathic
pulmonary
fibrosis
(IPF)
is
a
lethal
disorder
characterized
by
relentless
progression
of
lung
that
causes
respiratory
failure
and
early
death.
Currently,
no
curative
treatments
are
available,
existing
therapies
include
limited
selection
antifibrotic
agents
only
slow
disease
progression.
The
development
novel
therapeutics
has
been
hindered
understanding
the
disease's
etiology
pathogenesis.
A
significant
challenge
in
developing
new
IPF
lack
vitro
models
accurately
replicate
crucial
microenvironments.
In
response,
three-dimensional
(3D)
have
emerged
as
powerful
tools
for
replicating
organ-level
microenvironments
seen
vivo.
This
review
summarizes
state
art
advanced
3D
mimic
many
physiological
pathological
processes
observed
IPF.
We
begin
with
brief
overview
conventional
models,
such
2D
cell
cultures
animal
then
explore
more
focusing
on
lung-on-a-chip
systems.
discuss
current
challenges
future
research
opportunities
this
field,
aiming
to
advance
devices
assess
effectiveness
treatments.
